Introduction
Cardiac resynchronization therapy (CRT) is an established therapy for symptomatic patients with heart failure (HF), a reduced left ventricular ejection fraction (LVEF), and electrical dyssynchrony.
1 -8 Previous reports have shown that women may obtain greater benefit than men from CRT but the reason for this has not been fully clarified. Healthy women have smaller hearts 9 and a slightly shorter QRS duration 10, 11 than men and have been reported to benefit from CRT at a shorter QRS duration. 12, 13 In trials of CRT, women are also more likely to have non-ischaemic cardiomyopathy and left bundle branch block (LBBB), 14 two characteristics that are associated with greater reverse left ventricular (LV) remodelling with CRT 15 and hence potentially, with greater clinical benefit. Individual patient-data (IPD) meta-analysis allows investigation of the interaction amongst variables that conventional meta-analysis of aggregate data does not. In a previous IPD meta-analysis, we identified QRS duration as the only independent predictor of morbidity and mortality benefit after adjusting for other variables.
16
In this IPD meta-analysis, we explored differences in the benefits of CRT for men and women and whether these appeared directly related to sex or whether sex acted as a surrogate for other features that might provide plausible alternative explanations.
Methods
Individual-patient data from five substantial randomized controlled trials comparing CRT to no CRT with at least 6-month follow-up sponsored by Medtronic were used in this analysis. Data were pooled on 4317 patients comparing either CRT with no active control (no device or back-up pacing) (CARE-HF, 3 MIRACLE, 1 REVERSE 4,5 ) or CRT-D with implantable cardioverter-defibrillator (ICD) (REVERSE, 4, 5 MIRACLE ICD, 6 RAFT). 7 In the control arm back-up right ventricular pacing (VVI) was programmed to allow for intrinsic rhythm as much as possible and was VVI-30 in MIRACLE 1 and VVI-35 in MIRACLE ICD 6 and REVERSE. 4, 5 In order to create a more homogeneous population, patients in New York Heart Association (NYHA) class I (n = 107 from REVERSE) and those in atrial fibrillation or with a pre-existing pacemaker (n = 338 from RAFT) were excluded. The remaining patients were in sinus rhythm with NYHA class III/IV (CARE-HF, MIRACLE, MIR-ACLE ICD) or NYHA class II (MIRACLE ICD, REVERSE) and on guideline-recommended HF therapy before being randomized.
The two outcomes of interest specified for this analysis were all-cause mortality and the composite of first hospitalization for HF (HFH) or all-cause mortality. Hospitalizations were adjudicated by committees blinded to treatment allocation in each study.
Our previous univariate analyses 16 demonstrated that the baseline variables: age, sex, NYHA class, ischaemic aetiology, QRS duration, LVEF, beta-blocker use, and systolic blood pressure predicted clinical outcomes. Thus, these variables, considered the 'core covariates', were included in all models. Prior analyses also showed QRS duration to have a linear interaction with the effect of CRT for mortality, and a non-linear interaction for the composite of mortality or first HFH. 16 Core-laboratory values were used for electrocardiographic measurements in all studies and for echocardiographic assessment of LVEF in all studies except RAFT. Body mass index (BMI) 
Statistics
Analyses were conducted according to the intention-to-treat principle meaning that they included those patients who failed to receive their treatment assignment. 16 Continuously distributed data are shown as both mean and standard deviation and median, interquartile (IQR) and full range. Categorical data are shown as percentages. Because data were pooled from multiple studies which may be heterogeneous for one or more unaccounted factors affecting outcomes, shared frailty models including the 'core covariates' were used for both endpoints for each gender subgroup, with random effects for each study following a gamma distribution. Consistent with the findings of prior analyses, for mortality/first HFH, a model with both a linear and non-linear interaction term between QRS duration and CRT response was fit, while for mortality alone only a linear interaction term was fit. Quantitative variables (age, LVEF, QRS duration, systolic blood pressure) were treated as continuous variables in the models. QRS duration was centered by subtracting 120 ms for each QRS duration. 2 Patients in NYHA class III were enrolled in all but one study 5 and served as the default for calculating hazard rate. To assess variability of the results, 95% bootstrap confidence intervals were determined for each set of hazard ratios.
To study sex, we first tested CRT response over the range of QRS durations separately for men and women. Next, we established significant differences in baseline characteristics between men and women regarding HF aetiology, QRS morphology, LV end-diastolic diameter (LVEDD), and anthropometric data such as height, BMI, and LBM. T-tests were used to compare continuous measures, while chi-square tests were used to test ordinal and qualitative characteristics. Based on differences observed between men and women, men were partitioned into terciles by height, and frailty models including the 'core covariates' (excluding sex) were fit for comparison with women. Patients were also partitioned by sex and aetiology, and event rates per 100 patient years were calculated for each subgroup.
To investigate the relationship between height and the effect of CRT further, frailty models were fit for both mortality and mortality/HFH with the 'core covariate' main effects (excluding sex), main effects for CRT, normalized QRS duration and height, and the interaction effects for CRT with normalized QRS duration and normalized height. For each interaction term, the model tested a linear interaction effect for each interaction term, and a non-linear interaction effect incorporating a third-order P-spline with 4 degrees of freedom, which allows for fitting complicated curvilinear patterns. The latter interaction term was tested to determine if the hazard ratio for CRT changes over different heights and different QRS duration subgroups in a non-linear manner. The predicted values from each model were used to determine and plot the estimated hazard ratio of CRT for QRS duration and height as continuous measures. A similar model was fit with LBM substituted for height.
A sub-analysis was performed on the patients who also had LVEDD available, to assess whether the effect of height was a surrogate for LV size. The analysis added a main effect for LVEDD and an interaction effect for LVEDD with CRT to the overall model assessing height. A sub-analysis was also done involving the subset of patients in whom LV end-systolic volume (LVESV) was available. 
Results
Following exclusion of patients for missing LVEF, QRS width, or systolic blood pressure, a total of 3776 (97.5% of available randomized patients) were included in some or all of the analyses ( Figure 1) . Measurements of height were missing in a further 280 patients. In an additional 1023 patients, mainly from RAFT, LVEDD was not reported (Figure 1 ). The median (IQR) follow-up was 23.5 (6.2-38.3) months.
Patient characteristics
The median (IQR) age of patients was 66 (58-72) years and 794 (22.7%) were women ( . QRS duration and prevalence of LBBB was similar across terciles. The height of women ranged between 120.9-185.9 cm. Due to the smaller sample size, for the purpose of the event rate analysis women's heights were therefore divided into two categories based on a median of 160 cm.
Cardiac resynchronization therapy effect By sex in relation to QRS duration
Sex did not predict the response to CRT after accounting for other covariates. An interaction between CRT and QRS duration was observed for each sex. For the composite outcome, control for men (black lines) and women (red lines). (A) Relationship between the effect of CRT on mortality or first heart failure hospitalization (HFH) and QRS duration. (B) Corresponding relationship for mortality. The intersection of the 95% confidence interval and the line indicating a hazard ratio of 1.0 (no effect) indicates the QRS duration above which there is a high certainty of response.
a non-linear interaction was observed for men (P = 0.034) and for women (P = 0.049). For mortality alone, a linear interaction was observed for men (P = 0.0059) and, with less certainty, for women (P = 0.065). For both endpoints trends toward greater benefit amongst women were observed over the QRS duration range of 130-170 ms (Figure 2 
By aetiology and sex
QRS duration was smaller among patients with IHD in both men and women. For patients with IHD, more women (81.5%) than men (71.2%) had LBBB. Overall, patients with IHD had higher event rates regardless of sex or whether they were assigned to CRT ( Table 3 ). The benefits of CRT on outcomes were similar for women and men with IHD, whereas for patients without IHD the observed benefit of CRT was greater among women.
By height and sex in relation to QRS duration
The distribution of the lowest tercile of height amongst men [168 cm (165-170)] overlapped that for women [160 cm (156-166)], with approximately 94% of women having a height within the range of the lowest tercile of men. For the composite outcome, there was a linear interaction between QRS duration and the effect of CRT for each tercile of height for men ( Figure 3A) . The estimated effect of CRT on the composite outcome was greatest in the shortest tercile of men for whom benefit appeared to persist even when QRS duration was <130 ms. Similar results were noted for all-cause mortality ( Figure 3B ). The estimated effect of CRT on morbidity and mortality for the shortest tercile of men was similar to that observed for women and greater than in the two taller terciles of men. Bisecting women by height showed similar estimated hazard ratios across height among women ( Table 4 ). In the patients assigned to the control group, the event rates were higher in shorter patients (lowest tercile of men and lower half of women by height range).
Main modelling results for outcomes and interaction with effect of cardiac resynchronization therapy
Interaction between height and CRT, accounting for other covariates, was further assessed by ignoring sex and treating height as a continuous variable. Models adjusting for previously determined significant covariate main effects, as well as interaction between QRS duration and CRT, showed a linear interaction between height and CRT (P = 0.013) for mortality/HFH (Table 5 ), but not for mortality alone. Plotting the estimated hazard ratio for both height and QRS showed that the effect of CRT on the composite outcome was most pronounced amongst shorter patients with QRS between 160 and 190 ms ( Figure 4) . As can be seen in Figure 4B , the greater the QRS duration and the shorter the height, the lower the estimated hazard ratio for CRT benefit. This contour plot suggests that for patients with a QRS duration ≥150 ms, taller patients may still benefit from CRT as the estimated hazard ratio for patients . When an interaction term for sex and CRT was added to the composite outcome model, the height/CRT interaction term was no longer significant, suggesting confounding between the effect of sex and height. The model for the composite outcome was repeated substituting LBM for height, but neither the main effect for LBM (P = 0.61) nor the interaction with CRT, both linear (P = 0.089) and non-linear (P = 0.28), were statistically significant.
Measurements of both height and LVEDD were available for 2473 patients. Women had smaller LV dimensions than men, but LVEDD varied little across terciles of height for men ( Table 2) . LVEDD corrected for height was similar in women and men in the shortest two terciles of height, but was smaller in the tallest men. When the model for the composite outcome was expanded to include a main effect for LVEDD and an interaction effect for LVEDD with CRT, the interaction between height and CRT remained significant. Although the main effect for LVEDD was also significant, the interaction between LVEDD and CRT was not (supplementary material online, Table S1 ). This suggests that height may not simply be a surrogate for LV size.
Finally, to assess the potential confounding effect of LVESV, a model for the composite outcome was fit with interaction effects for CRT with QRS duration, and CRT with LVESV, along with main effects for age, NYHA class, baseline beta-blocker usage, aetiology, LVEF, QRS duration, LVESV, and systolic blood pressure. While the interaction effect for QRS duration remained significant, neither the main effect for LVESV (P = 0.32) nor the interaction between LVESV with CRT (P = 0.85) was significant. Consequently, further analyses including both LVESV and height were not explored.
Discussion
In this IPD meta-analysis, height and QRS duration but not sex independently predicted the ability of CRT to reduce the composite appeared to account for why CRT conferred greater benefit for women than for men. Sex may thus act as a surrogate for height and possibly for other factors, such as QRS morphology, aetiology of ventricular dysfunction, or LV dimensions, that all may influence the response to CRT. It is unknown, however, whether the possible confounding results in sex were masking the effects of these factors or vice versa, as the modelling could not effectively assess . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . the possible influence of sex when adjusting for height. Men significantly more often had IHD than women, with higher observed rates across all terciles, making it less likely that our results across terciles of men were explained by difference in presence of IHD. Our results suggest that although QRS duration is the key selection criterion for CRT, stature might also be taken into account in patient selection for CRT when QRS duration lies in the range of 130-160 ms. Historically, in clinical trials of CRT, only 20% of patients enrolled were women, making it difficult in individual studies to interpret possible differences between the sexes in their response to CRT. Conventional meta-analysis of aggregate data increases the power to detect the effect of an intervention in subgroups but unlike IPD does not permit investigation of the interaction between sex and other variables. Our prior IPD meta-analysis showed that sex was not an independent predictor of the effect of CRT on morbidity . or mortality after adjusting for other variables; only QRS duration predicted benefit. 16 In this analysis, we show that this relationship between QRS duration and the benefit of CRT exists for both men and women.
Retrospective analyses of the MADIT-CRT trial of HF patients in NYHA class I-II and not included in this analysis, suggested that LBBB, a subgroup that was not pre-specified, was associated with greater benefit from CRT, 13 which has had a major impact on CRT guidelines. 2, 8 LBBB is more prevalent amongst women, which might explain differences in the effect of CRT between the sexes.
11 -13 Others have suggested that amongst patients with LBBB, women benefit from CRT-D at shorter QRS durations than men. 18 However, in an analysis of MADIT-CRT confined to patients with LBBB, the effect of CRT-D on both morbidity and mortality was greater amongst women, 19 suggesting that female sex contributed to CRT benefit. Accordingly, differences in the 789 Figure 4 Estimated hazard ratios (Z-axis) for the effects of cardiac resynchronization therapy (CRT) vs. control on mortality/first heart failure hospitalization with QRS duration plotted on the X-axis and height in cm plotted on the Y-axis. Hazard ratio 1 marked with line (A) and a contour plot for CRT hazard ratio of mortality/first heart failure hospitalization by QRS and height (B). The contours reflect the CRT hazard ratio for different combinations of QRS duration and height generated from A. This 'overhead view' was created to facilitate the ranges of height (Y-axis) and QRS duration (X-axis) for different CRT hazard ratios. Lighter blue colour corresponds to greater CRT benefit (i.e. lower hazard ratio).
prevalence of LBBB do not appear to be key to the greater benefit of CRT amongst women. Analyses of trials of CRT other than MADIT-CRT have generally not supported a greater benefit of CRT amongst patients with LBBB. 20 In an IPD meta-analysis larger than the present one and comprising all of the main trials of CRT, including from three different manufacturers and across a range of . . . . . . . . . . . . . . . . . .
NYHA classes, older age, QRS duration >150 ms, and female sex were associated with a greater prognostic benefit from CRT; LBBB was not an independent predictor of benefit although the authors retained it in their prognostic model. 21 However, QRS duration was not analysed as a continuous variable, which weakens its contribution in prediction models. In the current IPD meta-analysis, where QRS duration was used as a continuous variable, LBBB was more common amongst women but it was not an independent predictor of response after accounting for QRS duration. In CRT trials, women are also less likely to have IHD as the cause of LV dysfunction.
14 Patients with IHD in CRT trials are less likely to have LBBB and have shorter QRS durations, smaller LV volumes, and less pronounced reverse LV remodelling after CRT, 15 all of which might be expected to lead to a worse response to CRT. In our analysis, although patients with IHD had a worse outcome than those with dilated cardiomyopathy, they obtained similar relative and therefore somewhat greater absolute benefit from CRT regardless of sex. 16 This suggests that mechanisms other than reverse remodelling account for some of the therapeutic benefits of CRT 16, 19, 22 and that IHD should not be used as a selection criterion.
In a previous single centre study of 212 patients with dilated cardiomyopathy and LBBB, LV reverse remodelling with CRT was greater in women than in men and occurred at smaller QRS duration.
12 This effect was not explained by differences in body surface area but by adjustment for LV mass and end-diastolic volume. 23 In our analysis, median LVEDD was smaller amongst women compared to men regardless of tercile in height. On average, healthy women have smaller hearts than men 24 but this difference is largely accounted for by differences in height. 25 Shorter patients will have relatively more LV dilatation for a given LV dimension than a tall person. In our analysis, after correction for height, women and men in the shorter two terciles had similar LVEDD, but men in the tallest tercile had relatively less LV dilatation. The greater benefit of CRT in women and shorter men might be because of greater LV dilatation relative to their pre-morbid state. However, we did not find that LVEDD predicted benefit from CRT, whether or not height was included in the model. Shorter patients may be at higher risk for cardiovascular events. In population studies, shorter patients are at higher risk of coronary artery disease and stroke 26 and greater risk of new-onset HF. 27 In our analysis, women and men had similar BMI but, as expected, 28 LBM was lower in women as a percentage of body weight. Higher BMI is associated with a lower mortality for patients with HF, 25, 29 but BMI does not distinguish between fat and LBM. Individuals with similar BMI may have very different body compositions.
An important limitation of this analysis was the restriction to those studies in which we had access to IPD. One distinction is that the mean age in this IPD is lower than the mean age of the overall broad HF population and in HF surveys. Therefore, care should be taken in interpreting post-hoc analyses of subgroup data and in extrapolating data gathered from patients selected for a clinical trial to the wider patient population that might be considered for CRT. Therefore, and despite stemming from an IPD meta-analysis, our study results do not allow firm conclusions, but remain hypothesis generating. Our analysis included a large number of patients with heterogeneity in symptom severity and intervention (ICD vs. CRT) but found that no measured patient characteristic other than QRS duration and height influenced the clinical benefit of CRT. Choice of baseline covariates to evaluate was pre-determined by constituent trials and pre-defined for this analysis. was required for subgroups. Finally, many patients had missing data on ventricular dimensions and volumes, which will have weakened the power to show interactions for these variables. Race was not taken into consideration in this analysis but most patients were of Caucasian origin. Whether race influences the relationship between QRS duration and the effect of CRT is unknown but amongst healthy individuals, Africans and Asians of both sexes have a shorter QRS duration than Caucasians.
10,30
In conclusion, QRS duration is the strongest predictor of the likelihood that CRT will reduce morbidity and mortality for patients with symptomatic HF, a reduced LVEF and in sinus rhythm, but patients who are shorter in height may also be more likely to benefit. Differences in height might account for the observation that women tend to benefit more from CRT than men. Whether height-corrected QRS duration should be used to select patients for CRT deserves further exploration.
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